An active control group is a group of participants in a clinical trial who receive an existing, proven treatment instead of a placebo or no treatment at all. The new drug or therapy being tested is then compared against this known treatment to see how it stacks up. This design is especially common when it would be unethical to give participants a sugar pill because an effective treatment already exists.
How It Differs From a Placebo Group
In a placebo-controlled trial, one group gets the experimental treatment and the other gets an inactive substance, like a sugar pill or saline injection. The goal is straightforward: does the new treatment work better than nothing? An active control flips that question. Instead of asking “does this drug work at all,” it asks “does this drug work as well as, or better than, what we already have?”
That distinction matters because the two designs answer fundamentally different questions. A placebo comparison tells you whether a drug has any effect. An active control comparison tells you whether a drug is a viable alternative to current treatment, or potentially an improvement over it.
Why Researchers Use Active Controls
The primary reason is ethics. The World Medical Association’s Declaration of Helsinki, the most influential set of ethical principles for medical research, states that new interventions must be tested against the best proven treatment when one exists. Giving a patient a placebo when a life-saving or disease-modifying drug is available would expose them to unnecessary harm.
Think of cancer treatment trials. You can’t ethically randomize patients with a treatable cancer into a group that receives no therapy. The same applies to conditions like heart failure, epilepsy, or HIV, where withholding treatment could cause irreversible damage or death. In these situations, the new drug is compared to whatever the current standard of care happens to be.
The Declaration does allow placebo use in some narrow circumstances: when no proven treatment exists, or when there are compelling scientific reasons and participants won’t face serious or irreversible harm from not receiving the standard therapy.
Three Types of Active Control Trials
Researchers design active control trials with one of three goals in mind, and the goal shapes everything about how the trial is run and analyzed.
- Superiority trials aim to show that the new treatment is better than the existing one. This is the most ambitious goal and requires clear statistical evidence that the new drug outperforms the comparator.
- Non-inferiority trials aim to show that the new treatment is not meaningfully worse than the existing one. The researchers define an acceptable margin in advance. If the new drug’s performance falls within that margin, it passes. This is the most common type of active control trial.
- Equivalence trials aim to show that two treatments perform similarly, falling within a tight range of each other. These are less common and require an even narrower margin than non-inferiority trials.
Non-inferiority trials are particularly useful when a new drug offers practical advantages over the standard, like fewer side effects, easier dosing, or lower cost. Even if it’s not more effective, proving it works nearly as well can justify its use. The FDA notes that the intent of these trials “is not to show that the new drug is equivalent, but rather that it is not materially worse than the control.”
Active Placebos: A Special Case
There’s a lesser-known variant called an active placebo, which is different from an active control. An active placebo is a substance that mimics the side effects of the drug being tested but has no therapeutic benefit for the condition being studied. It’s designed to prevent participants from figuring out whether they’re on the real drug based on how it makes them feel.
For example, in trials of certain antidepressants that cause dry mouth and drowsiness, an active placebo might be a drug that produces similar sensations without affecting depression. A standard placebo only matches the appearance, taste, and texture of the real drug. An active placebo goes further by replicating internal sensations, making the blinding more convincing. This helps researchers separate genuine therapeutic effects from placebo responses that are amplified when participants guess they’re on the real drug.
The Double-Dummy Technique
One practical challenge with active control trials is keeping participants and researchers blind to who’s getting which treatment. If the new drug is a pill and the existing treatment is an injection, participants would immediately know which group they’re in. That knowledge alone can skew results.
To solve this, researchers use a technique called double-dummy. Each participant receives both a pill and an injection, but one of the two is always inactive. Group A gets the real pill plus a dummy injection. Group B gets a dummy pill plus the real injection. Nobody can tell which treatment they’re actually receiving, because everyone is taking both forms. Early examples of this approach date back to the 1960s, when researchers comparing two arthritis drugs with different-looking tablets gave each group the active version of one drug alongside an inert tablet matching the other.
The Assay Sensitivity Problem
Active control trials have a significant statistical weakness that placebo-controlled trials don’t. It’s called assay sensitivity: the trial’s ability to detect a difference between treatments when one actually exists.
Here’s the core issue. In a non-inferiority trial, there’s no placebo group, so you can’t directly measure whether the active control actually worked in this particular trial. You’re relying on historical data showing the control drug is effective. But what if something about this specific trial (the patient population, how the drug was administered, adherence rates) meant the control drug didn’t perform as well as expected? If both the new drug and the control performed poorly, the trial might conclude they’re equivalent when really neither worked well.
Researchers across the clinical trial community agree this is the hardest challenge to overcome. It is technically impossible to prove assay sensitivity in a non-inferiority trial unless a placebo arm is added, which often can’t be done for ethical reasons. This creates a genuine tension between protecting participants and producing clean statistical evidence.
Larger Sample Sizes Required
Active control trials generally need more participants than placebo-controlled trials. The reason is mathematical: the difference between two effective treatments is expected to be small, so you need more data points to reliably detect it. Calculations show that using conventional statistical methods to compare a new drug against an active control, rather than a placebo, dramatically increases the required sample size. This makes these trials more expensive and time-consuming to run.
Real-World Examples
Active control designs are common in cardiovascular research, oncology, and any field where proven treatments exist. In stroke prevention, trials testing newer blood-thinning drugs compared them against warfarin, a well-established anticoagulant. The landmark trial of dabigatran versus warfarin in patients with atrial fibrillation is a widely cited example.
In diabetes research, the CAROLINA trial compared linagliptin against glimepiride to evaluate cardiovascular outcomes in patients with type 2 diabetes. The ongoing SURPASS CVOT trial uses a similar approach, testing tirzepatide against dulaglutide. In both cases, the question isn’t whether the drug works better than nothing. It’s whether it performs at least as well as what doctors are already prescribing, while potentially offering other benefits like fewer side effects or additional metabolic improvements.
How Active Controls Are Chosen
Not just any existing drug qualifies as an active control. The comparator needs to have well-established efficacy for the condition being studied, supported by previous trial data. It should have a similar indication and ideally a similar formulation as the drug being tested. Researchers also need to understand the comparator’s relationship with the outcome being measured, because if that relationship is unclear, the trial results become difficult to interpret.
Choosing the wrong comparator can undermine an entire trial. If the active control’s historical effectiveness was demonstrated in a different patient population or at a different dose, the assumptions underlying the trial’s statistical framework may not hold. This is why regulatory agencies like the FDA require detailed justification for both the choice of comparator and the non-inferiority margin before the trial begins.